Rigel Pharmaceuticals Net Worth
Rigel Pharmaceuticals Net Worth Breakdown | RIGL |
Rigel Pharmaceuticals Net Worth Analysis
Rigel Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Rigel Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Rigel Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Rigel Pharmaceuticals' net worth analysis. One common approach is to calculate Rigel Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Rigel Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Rigel Pharmaceuticals' net worth. This approach calculates the present value of Rigel Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Rigel Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Rigel Pharmaceuticals' net worth. This involves comparing Rigel Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Rigel Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Rigel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rigel Pharmaceuticals' net worth research are outlined below:
| Rigel Pharmaceuticals had very high historical volatility over the last 90 days | |
| Rigel Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| About 69.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Furey Raymond J. of 7850 shares of Rigel Pharmaceuticals at 12.7 subject to Rule 16b-3 |
Rigel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rigel Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rigel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Rigel Pharmaceuticals Target Price Consensus
Rigel target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Rigel Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Buy |
Most Rigel analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Rigel stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Rigel Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRigel Pharmaceuticals Target Price Projection
Rigel Pharmaceuticals' current and average target prices are 20.20 and 31.33, respectively. The current price of Rigel Pharmaceuticals is the price at which Rigel Pharmaceuticals is currently trading. On the other hand, Rigel Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Rigel Pharmaceuticals Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Rigel Pharmaceuticals Target Price
Know Rigel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rigel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rigel Pharmaceuticals backward and forwards among themselves. Rigel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rigel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 180.5 K | Hillsdale Investment Management Inc. | 2024-12-31 | 170.1 K | Goldman Sachs Group Inc | 2024-12-31 | 166.9 K | Northern Trust Corp | 2024-12-31 | 145.8 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 139.1 K | Norges Bank | 2024-12-31 | 129.5 K | Qube Research & Technologies | 2024-12-31 | 118 K | Ing Investment Management Llc | 2024-12-31 | 108.6 K | Los Angeles Capital Management Llc | 2024-12-31 | 86 K | Blackrock Inc | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M |
Follow Rigel Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 363.87 M.Market Cap |
|
Project Rigel Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.24 | 0.25 | |
| Return On Assets | 0.11 | 0.11 | |
| Return On Equity | 5.32 | 5.58 |
When accessing Rigel Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Rigel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rigel Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Rigel Pharmaceuticals' management efficiency
Rigel Pharmaceuticals has return on total asset (ROA) of 0.1075 % which means that it generated a profit of $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.13 this year. Return On Capital Employed is expected to rise to 0.25 this year. At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Non Currrent Assets Other will most likely fall to about 1.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.19 | 0.18 | |
| Tangible Book Value Per Share | (1.35) | (1.29) | |
| Enterprise Value Over EBITDA | 10.48 | 11.01 | |
| Price Book Value Ratio | 89.93 | 94.42 | |
| Enterprise Value Multiple | 10.48 | 11.01 | |
| Price Fair Value | 89.93 | 94.42 | |
| Enterprise Value | 322.1 M | 306 M |
At Rigel Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 1.9328 | Revenue | Quarterly Revenue Growth 0.609 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rigel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rigel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rigel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rigel Pharmaceuticals Corporate Filings
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 4th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Rigel Pharmaceuticals Earnings Estimation Breakdown
The calculation of Rigel Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Rigel Pharmaceuticals is estimated to be 0.0893 with the future projection ranging from a low of -0.08 to a high of 0.37. Please be aware that this consensus of annual earnings estimates for Rigel Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.08 Lowest | Expected EPS | 0.37 Highest |
Rigel Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Rigel Pharmaceuticals' value are higher than the current market price of the Rigel Pharmaceuticals stock. In this case, investors may conclude that Rigel Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Rigel Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 6 | 42.22% | 0.8 | 0.0893 | 0.99 |
Rigel Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Rigel Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Rigel Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Rigel Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Rigel Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Rigel Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Rigel Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Rigel Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Rigel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-04 | 2024-12-31 | 0.5789 | 0.8 | 0.2211 | 38 | ||
2024-11-07 | 2024-09-30 | 0.06 | 0.7 | 0.64 | 1066 | ||
2024-08-06 | 2024-06-30 | -0.29 | -0.06 | 0.23 | 79 | ||
2024-05-07 | 2024-03-31 | -0.03 | -0.05 | -0.02 | 66 | ||
2024-03-05 | 2023-12-31 | -0.03 | 0.0042 | 0.0342 | 114 | ||
2023-11-07 | 2023-09-30 | -0.07 | -0.03 | 0.04 | 57 | ||
2023-08-01 | 2023-06-30 | -0.08 | -0.04 | 0.04 | 50 | ||
2023-05-02 | 2023-03-31 | -0.1 | -0.08 | 0.02 | 20 | ||
2023-03-07 | 2022-12-31 | -0.11 | 0.01 | 0.12 | 109 | ||
2022-11-03 | 2022-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2022-08-02 | 2022-06-30 | -0.12 | -0.08 | 0.04 | 33 | ||
2022-05-03 | 2022-03-31 | -0.14 | -0.16 | -0.02 | 14 | ||
2022-03-01 | 2021-12-31 | -0.13 | -0.13 | 0.0 | 0 | ||
2021-11-02 | 2021-09-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2021-08-03 | 2021-06-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2021-05-05 | 2021-03-31 | 0.01 | 0.22 | 0.21 | 2100 | ||
2021-03-02 | 2020-12-31 | -0.11 | -0.11 | 0.0 | 0 | ||
2020-11-05 | 2020-09-30 | -0.12 | -0.08 | 0.04 | 33 | ||
2020-08-04 | 2020-06-30 | -0.13 | -0.1 | 0.03 | 23 | ||
2020-05-05 | 2020-03-31 | 0.13 | 0.13 | 0.0 | 0 | ||
2020-02-27 | 2019-12-31 | -0.08 | -0.1 | -0.02 | 25 | ||
2019-11-05 | 2019-09-30 | -0.11 | -0.07 | 0.04 | 36 | ||
2019-08-06 | 2019-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2019-05-07 | 2019-03-31 | -0.13 | -0.11 | 0.02 | 15 | ||
2019-02-28 | 2018-12-31 | 0.03 | 0.03 | 0.0 | 0 | ||
2018-11-06 | 2018-09-30 | -0.15 | -0.14 | 0.01 | 6 | ||
2018-08-08 | 2018-06-30 | -0.16 | -0.16 | 0.0 | 0 | ||
2018-05-01 | 2018-03-31 | -0.17 | -0.17 | 0.0 | 0 | ||
2018-03-06 | 2017-12-31 | -0.13 | -0.18 | -0.05 | 38 | ||
2017-11-07 | 2017-09-30 | -0.15 | -0.14 | 0.01 | 6 | ||
2017-08-01 | 2017-06-30 | -0.15 | -0.16 | -0.01 | 6 | ||
2017-05-02 | 2017-03-31 | -0.12 | -0.13 | -0.01 | 8 | ||
2017-03-07 | 2016-12-31 | -0.17 | -0.16 | 0.01 | 5 | ||
2016-11-01 | 2016-09-30 | -0.23 | -0.18 | 0.05 | 21 | ||
2016-08-02 | 2016-06-30 | -0.2 | -0.15 | 0.05 | 25 | ||
2016-05-03 | 2016-03-31 | -0.19 | -0.19 | 0.0 | 0 | ||
2016-03-08 | 2015-12-31 | -0.13 | -0.14 | -0.01 | 7 | ||
2015-11-03 | 2015-09-30 | -0.17 | -0.08 | 0.09 | 52 | ||
2015-08-04 | 2015-06-30 | -0.22 | -0.16 | 0.06 | 27 | ||
2015-05-07 | 2015-03-31 | -0.18 | -0.21 | -0.03 | 16 | ||
2015-03-03 | 2014-12-31 | -0.26 | -0.15 | 0.11 | 42 | ||
2014-11-04 | 2014-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2014-08-05 | 2014-06-30 | -0.25 | -0.29 | -0.04 | 16 | ||
2014-05-07 | 2014-03-31 | -0.25 | -0.25 | 0.0 | 0 | ||
2014-03-04 | 2013-12-31 | -0.25 | -0.19 | 0.06 | 24 | ||
2013-11-05 | 2013-09-30 | -0.29 | -0.25 | 0.04 | 13 | ||
2013-08-06 | 2013-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2013-05-07 | 2013-03-31 | -0.3 | -0.29 | 0.01 | 3 | ||
2013-03-05 | 2012-12-31 | -0.32 | -0.3 | 0.02 | 6 | ||
2012-11-06 | 2012-09-30 | -0.37 | -0.36 | 0.01 | 2 | ||
2012-08-07 | 2012-06-30 | -0.35 | -0.35 | 0.0 | 0 | ||
2012-05-01 | 2012-03-31 | -0.31 | -0.32 | -0.01 | 3 | ||
2012-03-06 | 2011-12-31 | -0.28 | -0.36 | -0.08 | 28 | ||
2011-11-01 | 2011-09-30 | -0.3 | -0.25 | 0.05 | 16 | ||
2011-08-02 | 2011-06-30 | -0.38 | -0.37 | 0.01 | 2 | ||
2011-05-03 | 2011-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2011-03-01 | 2010-12-31 | -0.36 | -0.33 | 0.03 | 8 | ||
2010-11-02 | 2010-09-30 | 0.62 | 0.96 | 0.34 | 54 | ||
2010-08-03 | 2010-06-30 | 0.47 | 0.51 | 0.04 | 8 | ||
2010-05-04 | 2010-03-31 | 0.11 | -0.43 | -0.54 | 490 | ||
2010-03-02 | 2009-12-31 | -0.45 | -0.48 | -0.03 | 6 | ||
2009-11-03 | 2009-09-30 | -0.58 | -0.7 | -0.12 | 20 | ||
2009-08-04 | 2009-06-30 | -0.81 | -0.81 | 0.0 | 0 | ||
2009-05-05 | 2009-03-31 | -0.99 | -0.82 | 0.17 | 17 | ||
2009-02-24 | 2008-12-31 | -0.97 | -0.91 | 0.06 | 6 | ||
2008-11-03 | 2008-09-30 | -0.87 | -1.03 | -0.16 | 18 | ||
2008-08-05 | 2008-06-30 | -0.69 | -0.93 | -0.24 | 34 | ||
2008-05-06 | 2008-03-31 | -0.62 | -0.79 | -0.17 | 27 | ||
2008-02-12 | 2007-12-31 | -0.43 | -0.61 | -0.18 | 41 | ||
2007-11-06 | 2007-09-30 | -0.57 | -0.61 | -0.04 | 7 | ||
2007-08-07 | 2007-06-30 | -0.63 | -0.68 | -0.05 | 7 | ||
2007-05-10 | 2007-03-31 | -0.67 | -0.68 | -0.01 | 1 | ||
2007-02-06 | 2006-12-31 | -0.64 | -0.62 | 0.02 | 3 | ||
2006-11-07 | 2006-09-30 | -0.47 | -0.46 | 0.01 | 2 | ||
2006-08-02 | 2006-06-30 | -0.56 | -0.09 | 0.47 | 83 | ||
2006-05-02 | 2006-03-31 | -0.32 | -0.34 | -0.02 | 6 | ||
2006-02-07 | 2005-12-31 | -0.43 | -0.36 | 0.07 | 16 | ||
2005-11-08 | 2005-09-30 | -0.61 | -0.56 | 0.05 | 8 | ||
2005-08-03 | 2005-06-30 | -0.71 | -0.62 | 0.09 | 12 | ||
2005-05-03 | 2005-03-31 | -0.48 | -0.57 | -0.09 | 18 | ||
2005-02-08 | 2004-12-31 | -0.69 | -0.75 | -0.06 | 8 | ||
2004-11-05 | 2004-09-30 | -0.71 | -0.88 | -0.17 | 23 | ||
2004-08-03 | 2004-06-30 | -0.74 | -0.68 | 0.06 | 8 | ||
2004-05-04 | 2004-03-31 | -0.78 | -0.81 | -0.03 | 3 | ||
2004-02-03 | 2003-12-31 | -0.71 | -0.8 | -0.09 | 12 | ||
2003-02-05 | 2002-12-31 | -2.16 | -1.62 | 0.54 | 25 | ||
2002-11-04 | 2002-09-30 | -1.8 | -1.98 | -0.18 | 10 | ||
2002-08-06 | 2002-06-30 | -1.35 | -2.07 | -0.72 | 53 | ||
2002-05-07 | 2002-03-31 | -1.53 | -1.71 | -0.18 | 11 | ||
2002-02-05 | 2001-12-31 | -1.84 | -1.44 | 0.4 | 21 | ||
2001-11-07 | 2001-09-30 | -1.53 | -1.53 | 0.0 | 0 | ||
2001-08-08 | 2001-06-30 | -0.99 | -1.8 | -0.81 | 81 | ||
2001-05-08 | 2001-03-31 | -1.44 | -0.99 | 0.45 | 31 | ||
2001-02-07 | 2000-12-31 | -2.34 | -3.24 | -0.9 | 38 |
Rigel Pharmaceuticals Corporate Management
| Raymond JD | General VP | Profile | |
| Tarek Sallam | Vice Marketing | Profile | |
| David Santos | Executive Officer | Profile | |
| Julie Patel | Senior Resources | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 17.867 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth 0.609 | Return On Assets |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.